Geopolitical Biopharma Friction: U.S. House Committee Launches National Security Probe into Merck and AbbVie Clinical Trials in China

Key Development

The chair of the U.S. House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party, Republican Representative John Moolenaar, has formally opened a sweeping national security investigation targeting five premier American drugmakers: Merck & Co., AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb (BMS). The high-stakes congressional probe focuses strictly on whether these multinational corporations’ clinical trials executed in China have inadvertently transferred advanced biotechnology intellectual property or optimized biological capabilities linked to the Chinese military.

In official letters transmitted to Merck CEO Robert Davis and AbbVie CEO Robert Michael, the committee mandated the corporations to supply exhaustive verification dockets by July 17, 2026. The required disclosures focus on internal due diligence protocols, data protection architectures, and ethical consent monitoring at their operational trial networks across China, specifically isolating high-risk nodes within the Xinjiang region and medical facilities affiliated with the People’s Liberation Army (PLA).

Why It Matters

• Protecting Biopharma IP Moats: Congressional regulators assert that executing cutting-edge clinical infrastructure within Chinese military hospitals (Merck collaborating on 40 studies; AbbVie sponsoring 16) places proprietary American small-molecule and large-molecule intellectual property at severe risk of systemic forced technology transfer.

• Enforcing Human Rights and Consent Compliance: The probe concentrates heavily on clinical trial sites operating in the Xinjiang region (31 sites for Merck; 17 for AbbVie). Letters point out documented lapses in securing valid, un-coerced informed consent from trial participants, triggering compliance risks mirrored under the spirit of the Uyghur Forced Labor Prevention Act (UFLPA).

• Triggering Immediate Capital Market Volatility: Following the exposure of the congressional letters, dominant pharmaceutical equities experienced immediate downward corrections in early trading sessions: Eli Lilly, Pfizer, Merck, and BMS contracted by nearly 2%, while AbbVie dropped 1%.

• Escalating the “Biosecure” Framework: This probe expands upon the foundational Biosecure Act signed into law by President Donald Trump late last year. It aligns with the newly introduced “Biotech Investment National Security Act,” designed to place outbound biotechnology licensing transactions, joint ventures, and capital allocations into China under strict national security screening.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the launch of this U.S. congressional investigation is a critical flashpoint signaling The End of Borderless Biomedical R&D across the international life sciences industry. Over the past two decades, China has systematically positioned itself as the world’s most cost-efficient and high-velocity theater for early-stage human clinical trials, leveraging aggressive regulatory streamlining, dense centralized patient populations, and heavy state subsidies. A review of global innovation metrics validates this structural migration: between 2015 and 2024, the United States’ absolute share of global early drug development programs collapsed from 48% to roughly 37%, whereas China’s footprint expanded from a minor 8% to over 32%.

American Big Pharma’s operational integration into the Chinese clinical research matrix is exceptionally deep, illustrated by global aggregators committing a record-breaking $138 billion in inbound licensing transaction volume in 2025 to control innovative Chinese experimental molecules. Consequently, installing strict federal geopolitical barriers introduces near-term operational gridlock for ongoing global R&D tracks.

The core challenge rests on the fact that China’s top-tier military medical centers are often the nation’s most sophisticated clinical institutions, housing the largest, most standardized patient registries and possessing the hardware specialized to evaluate highly complex modalities like CAR-T, gene therapies, and bispecific antibodies. Forcing American drugmakers to completely decouple from these high-volume nodes and the Xinjiang footprint will inevitably induce a 12-to-24-month delay across critical pipeline registration schedules (notably impacting Merck’s core oncology oncology clinical franchises or AbbVie’s immunology assets) due to the sheer friction of rerouting global patient enrollment initiatives to alternative geographic domains, structurally driving up per-molecule R&D overheads.

Market Implications

1. Accelerating a “China-Plus-One” Strategy for Clinical Development: U.S. biopharma aggregators will immediately activate geopolitical risk-mitigation playbooks. Capital deployment for Phase I and Phase II trials will likely shift away from Chinese territory, flowing into secondary Southeast Asian corridors (such as Vietnam, Thailand, and Malaysia) or Eastern Europe to secure compliant patient pools safely insulated from Washington’s security tracking.

2. Tightening Internal CMC and Regulatory Data Audits: The rigid July 17, 2026 compliance deadline will force Legal and Regulatory Affairs teams at Merck, AbbVie, and Pfizer to comprehensively audit two decades of historical data storage operations in China. Protocols governing Human Genetic Resources (HGR) tracking and localized Product Information File (PIF) compliance will undergo extensive hardening.

3. Depressing Valuations for Chinese Inbound Licensing Assets: Cross-border molecule-licensing and co-development deals involving Chinese biotechs will face immediate screening under outbound technological review structures. U.S. buyers will likely demand deep valuation discounts on Chinese biological assets to account for the heightened structural and legislative compliance friction imposed by Washington.

Ledger of Under-Investigation Clinical Trial Assets in China

Source: https://www.reuters.com/business/healthcare-pharmaceuticals/fda-allow-zyn-market-nicotine-pouches-less-harmful-than-cigarettes-axios-reports-2026-06-30/